Building the Future of Bioconjugate Supply: Integrating Payload-Linkers, Manufacturing and Commercial Scale-Up

As bioconjugate pipelines mature and commercial demand increases, companies face growing challenges in scaling development, manufacturing, formulation, and supply operations. Success requires more than expertise in conjugation - it depends on seamless integration across mammalian, payload-linker development, bioconjugation, drug product manufacturing, and supply chain management. In response to evolving industry needs, Lonza has announced an expansion to its payload-linker capabilities while continuing to strengthen its integrated bioconjugate offering across the molecule lifecycle. This presentation will explore how combining payload-linker innovation, bioconjugation expertise, and scalable manufacturing enables a more streamlined path from early development through commercialization. Attendees will gain insight into the growing importance of integrated solutions for reducing complexity, accelerating development timelines, and supporting future commercial demand. The discussion will also highlight how next-generation manufacturing capabilities are helping prepare the industry for the increasing scale and maturity of bioconjugate pipelines.